Antitope's senior management team comprises individuals with successful track records from a broad cross section of the biotechnology and pharmaceutical industry.
John Burt DPhil ACMA
Chief Executive Officer and Director
John joined PolyTherics in November 2010, initially as Chief Business Officer before becoming CEO in May 2011. He is CEO of the enlarged PolyTherics group and became a Director of Antitope in July 2013 when the two companies combined.
In 2004, John co-founded Thiakis, with Professor Sir Steve Bloom (Imperial College), which he led as CEO through to its acquisition by Wyeth in December 2008. Previously, John held a range of roles covering finance, technology licensing and business and corporate development roles with Vernalis, GlaxoSmithKline and Imperial Innovations. John holds a DPhil (molecular biology) from University of Oxford following his first degree in natural sciences at University of Cambridge.
Matthew Baker PhD
Chief Scientific Officer and Director
Matthew is a co-founder of Antitope and formerly VP for Biologics Discovery at Biovation Ltd, now a subsidiary of Merck KGaA. Matthew led an experienced team at Biovation/Merck which successfully developed novel biologics for inflammation, blood disorders, infection and cancer.
Sally Waterman PhD
Chief Operating Officer, PolyTherics and Director
Sally joined PolyTherics in October 2009 as COO and became a Director of Antitope in July 2013 when the companies combined. Sally’s previous roles include Director of Research & Development at Protherics (now part of BTG) and KS Biomedix (acquired by Xenova), VP of Non-clinical Development at Vernalis and Director of Scientific Operations at Pharmakopius (since acquired by PRA). Her early career was spent in regulatory affairs in GD Searle, Wyeth and Sterling Winthrop. Sally has been a member of several Boards, including Discerna, the first spin-out company from the Babraham Bioscience Technologies Limited. She has a BSc degree in Biological Sciences and obtained a PhD from the University of Reading for her research with Campylobacter jejuni.
Chief Financial Officer
Julian joined PolyTherics as its Chief Financial Officer (CFO) in September 2013. He was most recently the Chief Financial and Operations Officer at Imperial Innovations (AIM: IVO) where, in 2006, he managed its listing on the AIM market of the London Stock Exchange.
Prior to Imperial Innovations, Julian was the CFO of RadioScape Limited and Group Financial Controller of Mobile Systems International. Julian is a Chartered Accountant and has an MA in Engineering Science from Oxford University.
Frank Carr PhD
VP, Biologics Research
Formerly Chief Executive Officer at Biovation Ltd and was the inventor of the DeImmunisation™ technology. Previously he co-invented "germ-lining" humanization technology at Scotgen Biopharmaceuticals which is now established as a standard technology for humanization.
Tim Jones PhD
Formerly a Senior Research Manager at Biovation Ltd where he was responsible for the development of several deimmunised therapeutic antibodies and proteins.
Neil Butt PhD
VP, Business Development
Formerly a manager with PA Consulting Group with particular responsibility for projects with biopharmaceutical companies and for business development in the pharmaceutical industry.